Maze Therapeutics (MAZE) Change in Account Payables (2024 - 2026)

Maze Therapeutics has reported Change in Account Payables for 3 years, with the latest figure at $2.2 million in Q1 2026.

• Quarterly Change in Account Payables rose 282.04% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 159.87% YoY) and the FY2025 annual result came in at -$27000.0, up 86.76% from the prior year.
• Change in Account Payables grew to $2.2 million in Q1 2026 per MAZE's latest filing, from -$1.1 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $2.2 million in Q1 2026 and troughed at -$1.2 million in Q3 2024.
• A 3-year average of $220111.1 and a median of $387000.0 in 2024 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 338.27% in 2025, down 237.03% in 2025.
• Over 3 years, Change in Account Payables stood at $821000.0 in 2024, then sank by 237.03% to -$1.1 million in 2025, then jumped by 296.62% to $2.2 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $2.2 million, -$1.1 million, and -$748000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.